LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_002691.4:c.242G>A
POLD1
· NP_002682.2:p.(Arg81Gln)
· NM_002691.4
GRCh37: chr19:50902667 G>A
·
GRCh38: chr19:50399410 G>A
Gene:
POLD1
Transcript:
NM_002691.4
Final call
VUS
PM2 moderate
Variant details
Gene
POLD1
Transcript
NM_002691.4
Protein
NP_002682.2:p.(Arg81Gln)
gnomAD AF
6.195748477394812e-06 (v4.1)
ClinVar
Uncertain significance
OncoKB
Unknown Oncogenic Effect
Classification rationale
Interpretation summary
Generated evidence synthesis
1
PM2 Moderate: gnomAD v4.1 allele frequency is 6.19575e-06, below the 0.0001 cutoff.
Final determination:
Under generic ACMG/AMP 2015 rules, one Moderate criterion alone satisfies no pathogenic, likely pathogenic, benign, or likely benign combination, so the result is VUS.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| PS1 | Not assessed | Not assessed: no previously established pathogenic Arg81Gln variant from a different nucleotide change is documented; ClinVar classifies this variant as uncertain significance. |
clinvar
|
| PS2 | Not assessed | Not assessed: no documented proband phenotype, family-history status, or confirmed maternity and paternity is available for this variant. |
clinvar
|
| PS3 | Not assessed | Not assessed: no variant-specific validated in vitro or in vivo functional assay, controls, or reproducibility data were identified for POLD1 c.242G>A (p.Arg81Gln). |
PMID:25741868
|
| PS4 | Not assessed | Not assessed: no exact-variant case-control counts, odds ratio, or confidence interval were reported, so the PS4 requirement of OR/RR >5.0 cannot be evaluated. |
PMID:25394175
PMID:33850299
PMID:29056344
PMID:29950348
PMID:25741868
|
| PM1 | Not assessed | Not assessed: POLD1 R81 is outside the reported codons 245-571 proofreading domain and no hotspot was found, but a complete critical-domain assessment is unavailable. |
hotspots
PMID:29950348
|
| PM2 | Met | Met at Moderate: gnomAD v4.1 total AF is 6.19575e-06, below the 0.0001 PM2 extremely-low-frequency cutoff. |
gnomad_v4
gnomad_v2
PMID:25741868
|
| PM3 | Not assessed | Not assessed: no affected-proband observation or parental/offspring testing establishes this variant in trans with a pathogenic variant. |
clinvar
|
| PM4 | N/A | Not applicable: PM4 requires a protein-length change, and this is a missense variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| PM5 | Not met | Not met: the p.Arg81Gln comparator search found zero same-residue candidates and zero pathogenic same-residue missense comparators. |
pm5_candidates
clinvar
|
| PM6 | Not assessed | Not assessed: no assumed de novo occurrence or parental testing is documented for NM_002691.4:c.242G>A. |
clinvar
|
| PP1 | Not assessed | Not assessed: zero affected relatives and zero informative meioses are documented for segregation of this variant. |
|
| PP2 | Not assessed | Not assessed: no gene-wide benign-missense rate and no evidence establishing missense variants as a common POLD1 disease mechanism are supplied. |
|
| PP3 | Not met | Not met: missense REVEL score 0.307 is below the PP3 supporting threshold of >=0.644. |
revel
PMID:25741868
|
| PP4 | Not assessed | Not assessed: the available evidence gives no patient phenotype or family-history details demonstrating a highly specific single-gene disease presentation. |
|
| PP5 | Not met | Not met: ClinVar has zero expert-panel submissions and all five exact-variant laboratory submissions classify POLD1 c.242G>A as uncertain significance. |
clinvar
PMID:25394175
PMID:33850299
PMID:25741868
|
| BA1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 2.47e-06, far below the 0.05 BA1 stand-alone threshold. |
gnomad_v4
gnomad_v2
PMID:25741868
|
| BS1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 2.47e-06, below the generic BS1 threshold of 0.01. |
gnomad_v4
gnomad_v2
|
| BS2 | Not assessed | Not assessed: gnomAD allele counts do not document a healthy adult carrier, age, phenotype exclusion, inheritance, or full penetrance. |
gnomad_v4
gnomad_v2
|
| BS3 | Not assessed | Not assessed: no variant-specific validated assay demonstrated that POLD1 c.242G>A (p.Arg81Gln) has no damaging effect on protein function or splicing. |
PMID:25741868
|
| BS4 | Not assessed | Not assessed: no affected relatives tested negative for NM_002691.4:c.242G>A are documented. |
|
| BP1 | Not assessed | Not assessed: available evidence documents POLD1 missense disease associations but does not quantify whether disease is caused primarily by truncating variants. |
PMID:29950348
|
| BP2 | Not assessed | Not assessed: no parental, offspring, or haplotype data establish this variant in trans or cis with a pathogenic variant. |
clinvar
|
| BP3 | N/A | Not applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. |
pvs1_generic_framework
generic_acmg_combination_rules
|
| BP4 | Not met | Not met: missense REVEL score 0.307 exceeds the BP4 supporting threshold of <=0.29. |
revel
PMID:25741868
|
| BP5 | Not assessed | Not assessed: no exact-variant case evidence shows an alternate molecular basis for the patient's disease. |
clinvar
PMID:25394175
PMID:33850299
|
| BP6 | Not met | Not met: ClinVar has zero expert-panel submissions and no exact-variant Benign or Likely benign expert-panel classification. |
clinvar
|
| BP7 | N/A | Not applicable: BP7 requires a synonymous variant, and this is a missense variant. |
generic_acmg_combination_rules
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.